Ramosetron
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diarrhea-predominant Irritable Bowel Syndrome
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Trial Timeline
Oct 1, 2015 → Mar 31, 2018
NCT ID
NCT02612649About Ramosetron
Ramosetron is a pre-clinical stage product being developed by Astellas Pharma for Diarrhea-predominant Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02612649. Target conditions include Diarrhea-predominant Irritable Bowel Syndrome.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02612649 | Pre-clinical | Completed |
Competing Products
3 competing products in Diarrhea-predominant Irritable Bowel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM060 + Placebo | Astellas Pharma | Phase 3 | 77 |
| YM060 | Astellas Pharma | Phase 3 | 77 |
| Rifamycin SV 600mg t.i.d. + Rifamycin SV b.i.d. + Placebo + Placebo t.i.d. | Cosmo Pharmaceuticals | Phase 2 | 47 |